<DOC>
	<DOCNO>NCT00081029</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Intensity-modulated radiation therapy delivers thin beam radiation different strength directly tumor many angle . This type radiation therapy may reduce damage parotid ( salivary ) gland , prevent xerostomia ( dry mouth ) , improve quality life . It yet know whether intensity-modulated radiation therapy effective conventional radiation therapy prevent xerostomia improve quality life patient throat cancer . PURPOSE : This randomized phase III trial study intensity-modulated radiation therapy see well work compare conventional radiation therapy treat patient oropharyngeal hypopharyngeal cancer risk develop xerostomia cause radiation therapy .</brief_summary>
	<brief_title>Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy Treating Patients With Oropharyngeal Hypopharyngeal Cancer Who Are High Risk Radiation-Induced Xerostomia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare proportion patient oropharyngeal hypopharyngeal cancer xerostomia â‰¥ grade 2 one year treatment parotid-sparing intensity-modulated radiotherapy vs conventional radiotherapy . Secondary - Compare degree xerostomia quantitative measurement stimulate unstimulated salivary flow patient treat regimen . - Compare quality life patient treat regimen . - Compare local regional tumor control , time tumor progression , overall survival patient treat regimen . - Compare acute late side effect regimens patient . OUTLINE : This randomize , control , multicenter study . Patients stratify accord participate center site disease ( oropharynx v hypopharynx ) . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo parotid-sparing intensity-modulated radiotherapy daily , 5 day week , 6 week . - Arm II : Patients undergo conventional radiotherapy daily , 5 day week , 6 week . Salivary flow measurement perform baseline , week 4 radiotherapy , 2 week 3 , 6 , 12 , 24 month completion radiotherapy . Quality life assess baseline , 2 week , 3 , 6 , 12 , 18 , 24 month completion radiotherapy . Patients follow monthly 1 year , every 2 month 1 year , every 6 month 3 year . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 84 patient ( 42 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Xerostomia</mesh_term>
	<mesh_term>Radiation Injuries</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm oropharyngeal hypopharyngeal cancer Squamous cell undifferentiated carcinoma Stage T14 , N03 , M0 disease Primary tumor require radical radiotherapy parallel oppose lateral field bilateral cervical lymph node irradiation Radiotherapy either primary therapy postoperative ( adjuvant irradiation ) treatment Highrisk radiationinduced xerostomia conventional radiotherapy due irradiation majority parotid glands* NOTE : *Estimated mean dose parotid gland great 24 Gy conventional radiotherapy No bilateral N3 nodal disease No huge primary tumor ( exceed 10 cm diameter ) No contralateral lymphadenopathy adjacent involve contralateral parotid gland make parotid spar impossible No tumor base tongue spar contralateral parapharyngeal space contraindicate PATIENT CHARACTERISTICS : Age Not specify Performance status WHO 01 Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other Able undergo quality life salivary flow measurement ( dependent cognitive aptitude long availability ) Able complete selfassessed quality life questionnaire No prior concurrent illness would preclude study participation No preexisting salivary gland pathology interfere saliva production No prior malignancy except nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Prior neoadjuvant chemotherapy allow No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy See Disease Characteristics No prior radiotherapy head neck region No concurrent brachytherapy Surgery See Disease Characteristics Other No concurrent prophylactic amifostine pilocarpine</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>xerostomia</keyword>
	<keyword>radiation toxicity</keyword>
	<keyword>stage I squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage I squamous cell carcinoma oropharynx</keyword>
	<keyword>stage II squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage II squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
</DOC>